早发型子痫前期孕妇倍他米松药代动力学研究
该前瞻性单中心药代动力学研究纳入28例即将早产的孕妇,采用群体药代动力学模型分析倍他米松及其代谢物,并结合离体胎盘灌注与外植体实验。结果显示早发型子痫前期孕妇倍他米松清除率降低60%,暴露量中位数增加40%,胎盘可自由转运倍他米松并仅代谢为11-酮倍他米松。
要点
- 早发型子痫前期孕妇倍他米松清除率降低60%,暴露量增加40%
- 倍他米松可自由转运至胎儿循环,胎盘仅将其代谢为11-酮倍他米松
- 胎盘11β-HSD1 mRNA表达降低可能与暴露增加有关
核心结论
- 早发型子痫前期孕妇倍他米松暴露量升高,胎盘11β-HSD1表达降低可能起一定作用。
研究设计与样本
- 前瞻性单中心药代动力学研究,纳入28例即将早产并接受肌注倍他米松的孕妇,采集194份系列静脉血样。
- 离体实验采用健康足月胎盘灌注(n=3)及健康足月(n=4)与早发型子痫前期(n=4)胎盘外植体。
- 定量健康与早发型子痫前期胎盘中CYP3A4、CYP3A7、11β-HSD1和11β-HSD2的mRNA表达。
主要发现
- 群体药代动力学模型以二室非线性混合效应模型描述最佳。
- 早发型子痫前期孕妇倍他米松清除率为9.35 L/h,低于无子痫前期者的15.78 L/h,降低60%。
- 早发型子痫前期孕妇倍他米松暴露量中位数为1567 ng h/mL,较无子痫前期者的1114 ng h/mL增加40%。
- 离体胎盘灌注显示倍他米松可转运至胎儿循环,胎儿/母体比值为0.76 ± 0.05。
- 胎盘仅将倍他米松转化为11-酮倍他米松,早发型子痫前期与健康胎盘外植体转化比值分别为3.0 ± 2.2与1.4 ± 0.4每毫克组织(P = .27)。
临床怎么用
- 临床对早发型子痫前期孕妇使用倍他米松时应关注其暴露量升高,必要时加强监测。
局限性
- 研究为单中心、样本量有限,离体实验样本量小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: To enhance understanding of betamethasone and its metabolites' pharmacokinetics in pregnancy, specifically early-onset pre-eclampsia, through a population pharmacokinetic model. Additionally, to investigate the placental metabolism and transfer of betamethasone and its main metabolites. METHODS: A prospective, single-centre pharmacokinetic study was conducted in pregnant women (n = 28) with imminent preterm birth treated with intramuscular betamethasone. Betamethasone serum concentrations were determined from serial venous blood samples (n = 194). Placental transfer and metabolism were studied using ex vivo human placental perfusion (healthy term; n = 3) and placental explant experiments (healthy term, n = 4; early-onset pre-eclampsia, n = 4). Additionally, placental mRNA expression of CYP3A4, CYP3A7, 11β-hydroxysteroid dehydrogenase (HSD) 1 and 11β-HSD2 were quantified in healthy and early-onset pre-eclampsia placentas. RESULTS: The population pharmacokinetic model was best described by a 2-compartment nonlinear mixed effects model. Betamethasone clearance in early-onset pre-eclamptic women was 60% lower of that observed in women without pre-eclampsia (9.35 vs. 15.78 L/h), resulting in a 40% median increase in maternal betamethasone exposure (1567 vs. 1114 ng h/mL). Ex vivo experiments showed placental transfer of betamethasone to the foetal circulation (foetal-to-maternal ratio 0.76 ± 0.05 [in a perfused placental cotyledon]). The placenta only converted betamethasone into 11-ketobetamethasone, with similar ratios in early-onset pre-eclampsia and healthy placental explants (3.0 ± 2.2 vs. 1.4 ± 0.4 per mg tissue, P = .27). The expression of 11β-HSD1 mRNA was lower in early-onset pre-eclampsia placentas (P = .015), while placental CYP3A7 and 11β-HSD2 mRNA expression were similar. CONCLUSION: Women with early-onset pre-eclampsia have elevated betamethasone exposure. Betamethasone transfers freely into the foetal circulation, with placental metabolism resulting only in 11-ketobetamethasone. Decreased placental 11β-HSD1 expression may play a role in increased betamethasone exposure in early-onset pre-eclampsia.
引用
- Schoenmakers S, Li L, Kluivers ACM, et al. Pharmacokinetics of betamethasone in pre-eclampsia: An in vivo and ex vivo study. Br J Clin Pharmacol. 2025. PMID: 40083164. doi:10.1002/bcp.70035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。